Details
Stereochemistry | ACHIRAL |
Molecular Formula | C15H18ClN3O3S |
Molecular Weight | 355.84 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
OCCN1CCN(CC1)C(=O)CN2C(=O)SC3=C2C=C(Cl)C=C3
InChI
InChIKey=HTJXMOGUGMSZOG-UHFFFAOYSA-N
InChI=1S/C15H18ClN3O3S/c16-11-1-2-13-12(9-11)19(15(22)23-13)10-14(21)18-5-3-17(4-6-18)7-8-20/h1-2,9,20H,3-8,10H2
Tiaramide is an anti-inflammatory and analgesic drug, which was developed by Fujisawa Pharmaceutical (now Astellas pharma) and used in Japan under the name Solantol for the treatment of different pain and inflammatory disorders. Later on, Astellas recalled the product by reasons other than safety. The mechanism of tiaramide action is unknown.
Originator
Approval Year
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | SOLANTAL Approved UsePain management after surgery, tooth extraction and trauma, pain relief in arthritis, low back pain, cervical shoulder arm syndrome, pelvic inflammation, birth canal injuries, breast engorgement, herpes zoster, polymorphic exudative erythema, cystitis, epididymitis, uveitis, pericoronitis, acute upper respiratory tract inflammation. Launch Date1974 |
|||
Palliative | SOLANTOL Approved UsePain management after surgery, tooth extraction and trauma, pain relief in arthritis, low back pain, cervical shoulder arm syndrome, pelvic inflammation, birth canal injuries, breast engorgement, herpes zoster, polymorphic exudative erythema, cystitis, epididymitis, uveitis, pericoronitis, acute upper respiratory tract inflammation. Launch Date1974 |
PubMed
Title | Date | PubMed |
---|---|---|
Strategy for structure elucidation of drug metabolites derived from protonated molecules and (MS)n fragmentation of zotepine, tiaramide and their metabolites. | 2002 |
|
Synthesis and anti-inflammatory activity of certain piperazinylthienylpyridazine derivatives. | 2007 Jul |
|
Safety of selective cyclooxygenase-2 inhibitors and a basic non-steroidal anti-inflammatory drug (NSAID) in Japanese patients with NSAID-induced urticaria and/or angioedema: Comparison of meloxicam, etodolac and tiaramide. | 2007 Mar |
|
Evaluation of the interaction between nonsteroidal anti-inflammatory drugs and methotrexate using human organic anion transporter 3-transfected cells. | 2008 Oct 31 |
Sample Use Guides
The recommended dose is 1 tablet (100 mg) once daily. In patients with acute upper respiratory tract inflammation the dose may be increased up to 3 tablets.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/451335
Tiaramide in 10(-4) and 10(-5)M inhibited effectively the platelet aggregation caused by ADP.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C319
Created by
admin on Fri Dec 15 17:57:28 GMT 2023 , Edited by admin on Fri Dec 15 17:57:28 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
C003468
Created by
admin on Fri Dec 15 17:57:28 GMT 2023 , Edited by admin on Fri Dec 15 17:57:28 GMT 2023
|
PRIMARY | |||
|
BB17WGM686
Created by
admin on Fri Dec 15 17:57:28 GMT 2023 , Edited by admin on Fri Dec 15 17:57:28 GMT 2023
|
PRIMARY | |||
|
CHEMBL274239
Created by
admin on Fri Dec 15 17:57:28 GMT 2023 , Edited by admin on Fri Dec 15 17:57:28 GMT 2023
|
PRIMARY | |||
|
3070
Created by
admin on Fri Dec 15 17:57:28 GMT 2023 , Edited by admin on Fri Dec 15 17:57:28 GMT 2023
|
PRIMARY | |||
|
m10849
Created by
admin on Fri Dec 15 17:57:28 GMT 2023 , Edited by admin on Fri Dec 15 17:57:28 GMT 2023
|
PRIMARY | Merck Index | ||
|
5469
Created by
admin on Fri Dec 15 17:57:28 GMT 2023 , Edited by admin on Fri Dec 15 17:57:28 GMT 2023
|
PRIMARY | |||
|
DTXSID0023666
Created by
admin on Fri Dec 15 17:57:28 GMT 2023 , Edited by admin on Fri Dec 15 17:57:28 GMT 2023
|
PRIMARY | |||
|
251-083-7
Created by
admin on Fri Dec 15 17:57:28 GMT 2023 , Edited by admin on Fri Dec 15 17:57:28 GMT 2023
|
PRIMARY | |||
|
C152603
Created by
admin on Fri Dec 15 17:57:28 GMT 2023 , Edited by admin on Fri Dec 15 17:57:28 GMT 2023
|
PRIMARY | |||
|
2653
Created by
admin on Fri Dec 15 17:57:28 GMT 2023 , Edited by admin on Fri Dec 15 17:57:28 GMT 2023
|
PRIMARY | |||
|
SUB11013MIG
Created by
admin on Fri Dec 15 17:57:28 GMT 2023 , Edited by admin on Fri Dec 15 17:57:28 GMT 2023
|
PRIMARY | |||
|
100000082161
Created by
admin on Fri Dec 15 17:57:28 GMT 2023 , Edited by admin on Fri Dec 15 17:57:28 GMT 2023
|
PRIMARY | |||
|
32527-55-2
Created by
admin on Fri Dec 15 17:57:28 GMT 2023 , Edited by admin on Fri Dec 15 17:57:28 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
METABOLITE (PARENT)
METABOLITE (PARENT)
METABOLITE (PARENT)
METABOLITE (PARENT)
SALT/SOLVATE (PARENT)